This story has been updated to reflect NeoGenomics' estimate on the valuation of the common stock portion of the deal and include debt the firm has taken on to finance it.

NEW YORK (GenomeWeb) – NeoGenomics today announced it has signed a definitive agreement to acquire cancer molecular diagnostics firm Clarient in a cash and stock deal worth approximately $275 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.

Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.

A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.

In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.